Literature DB >> 22966044

Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route.

Fetweh H Al-Saleem1, Denise M Ancharski, Suresh G Joshi, M Elias, Ajay Singh, Zidoon Nasser, Lance L Simpson.   

Abstract

Botulinum toxin is a highly potent oral and inhalation poison, which means that the toxin must have an efficient mechanism for penetration of epithelial barriers. To date, three models for toxin passage across epithelial barriers have been proposed: (i) the toxin itself undergoes binding and transcytosis; (ii) an auxiliary protein, HA35, transports toxin from the apical to the basal side of epithelial cells; and (iii) an auxiliary protein, HA35, acts on the basal side of epithelial cells to disrupt tight junctions, and this permits paracellular flux of toxin. These models were evaluated by studying toxin absorption following inhalation exposure in mice. Three types of experiments were conducted. In the first, the potency of pure neurotoxin was compared with that of progenitor toxin complex, which contains HA35. The results showed that the rate and extent of toxin absorption, as well as the potency of absorbed toxin, did not depend upon, nor were they enhanced by, the presence of HA35. In the second type of experiment, the potencies of pure neurotoxin and progenitor toxin complex were compared in the absence or presence of antibodies on the apical side of epithelial cells. Antibodies directed against the neurotoxin protected against challenge, but antibodies against HA35 did not. In the final type of experiment, the potency of pure neurotoxin and toxin complex was compared in animals pretreated to deliver antibodies to the basal side of epithelial cells. Once again, antibodies directed against the neurotoxin provided resistance to challenge, but antibodies directed against HA35 did not. Taken collectively, the data indicate that the toxin by itself is capable of crossing epithelial barriers. The data do not support any hypothesis in which HA35 is essential for toxin penetration of epithelial barriers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966044      PMCID: PMC3497405          DOI: 10.1128/IAI.00669-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes.

Authors:  Y Fujinaga; K Inoue; T Nomura; J Sasaki; J C Marvaud; M R Popoff; S Kozaki; K Oguma
Journal:  FEBS Lett       Date:  2000-02-11       Impact factor: 4.124

2.  Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments.

Authors:  S G Joshi; M Elias; A Singh; F H Al-Saleem; D Ancharski; Z Nasser; T Takahashi; L L Simpson
Journal:  Neuroscience       Date:  2011-01-26       Impact factor: 3.590

3.  Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells.

Authors:  Chowdhury R Ahsan; György Hajnóczky; Andrew B Maksymowych; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2005-09-06       Impact factor: 4.030

Review 4.  Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin.

Authors:  Yukako Fujinaga
Journal:  J Biochem       Date:  2006-08       Impact factor: 3.387

5.  The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption.

Authors:  Takuhiro Matsumura; Yingji Jin; Yuko Kabumoto; Yuki Takegahara; Keiji Oguma; Wayne I Lencer; Yukako Fujinaga
Journal:  Cell Microbiol       Date:  2007-09-14       Impact factor: 3.715

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

8.  The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin.

Authors:  Yukako Fujinaga; Kaoru Inoue; Sadahiro Watanabe; Kenji Yokota; Yoshikazu Hirai; Eiko Nagamachi; Keiji Oguma
Journal:  Microbiology (Reading)       Date:  1997-12       Impact factor: 2.777

9.  Kinetics of growth and toxigenicity of Clostridium botulinum in experimental wound botulism.

Authors:  M Dezfulian; J G Bartlett
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

10.  Wound botulism in injection drug users.

Authors:  Wiltrud Maria Kalka-Moll; Ute Aurbach; Reiner Schaumann; Rosemarie Schwarz; Harald Seifert
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

View more
  5 in total

1.  Centrifugal microfluidic platform for ultrasensitive detection of botulinum toxin.

Authors:  Chung-Yan Koh; Ulrich Y Schaff; Matthew E Piccini; Larry H Stanker; Luisa W Cheng; Easwaran Ravichandran; Bal-Ram Singh; Greg J Sommer; Anup K Singh
Journal:  Anal Chem       Date:  2015-01-05       Impact factor: 6.986

2.  Translocation of botulinum neurotoxin serotype A and associated proteins across the intestinal epithelia.

Authors:  Tina I Lam; Larry H Stanker; Kwangkook Lee; Rongsheng Jin; Luisa W Cheng
Journal:  Cell Microbiol       Date:  2015-02-15       Impact factor: 3.715

3.  RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake.

Authors:  Fetweh H Al-Saleem; Rashmi Sharma; Rama Devudu Puligedda; Md Elias; Chandana Devi Kattala; Paul M Simon; Lance L Simpson; Scott K Dessain
Journal:  Toxins (Basel)       Date:  2017-05-19       Impact factor: 4.546

4.  A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.

Authors:  Doris M Snow; Ronald R Cobb; Juan Martinez; Isaac Finger-Baker; Laura Collins; Sara Terpening; Emily S Syar; Nancy Niemuth; Dean Kobs; Roy Barnewall; Shauna Farr-Jones; James D Marks; Milan T Tomic
Journal:  Toxins (Basel)       Date:  2021-01-05       Impact factor: 4.546

Review 5.  Mechanisms of Botulinum Toxin Type A Action on Pain.

Authors:  Ivica Matak; Kata Bölcskei; Lidija Bach-Rojecky; Zsuzsanna Helyes
Journal:  Toxins (Basel)       Date:  2019-08-05       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.